Not to be used in patients w/ type 1 diabetes or for diabetic ketoacidosis. Discontinue use if ketoacidosis & necrotizing fasciitis of the perineum (Fournier's gangrene) are suspected. Temporarily interrupt treatment in patients w/ complicated UTIs. Patients for whom empagliflozin-induced drop in BP pose a risk eg, w/ known CV disease, on antihypertensive therapy w/ history of hypotension or ≥75 yr. Assess renal function prior to & periodically during treatment. Monitor vol status & electrolytes in case of fluid loss. +ve test for glucose in urine. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May influence ability to drive & use machines. Not to be initiated in patients w/ eGFR <45 mL/min/1.73 m2
or CrCl <45 mL/min; ESRD or on dialysis. Not recommended in severe hepatic impairment. Hepatic injury. Not recommended during 2nd & 3rd trimester of pregnancy. Not to be used during lactation. Childn & adolescents. Not recommended in elderly ≥85 yr.